FocalTherics (FOCL) Q2 2026 Earnings Call Transcript
FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.
How this was made
The 30-second read
Why it matters
Near-term trading focus is likely on the combination of strong Q2 operating metrics and the CMS proposed 2027 facility payment increase, which management frames as supporting hospital investment. Medium-term focus includes FDA 510(k) submission for FocalConnect and indication expansion plans for BPH and endometriosis.
Market read
Strong Q2 growth and a specific reimbursement proposal are likely to be the main drivers for investor reassessment of demand durability and utilization scaling.
What to watch
Installed base is growing, but the excerpt does not provide gross margin, cash burn, or full-year guidance, which could limit how much of the operating momentum translates into earnings power.
Background
The piece is a Q2 2026 earnings call transcript for FocalTherics focused on HIFU revenue growth, Focal One system sales, installed base expansion, utilization, and regulatory and reimbursement updates.
Ticker impact
FocalTherics reports Q2 2026 results including $13.2M HIFU revenue (+39% YoY) and 13 Focal One system sales (+44% YoY).
Likely positive bias for FOCL shares, with upside skew if investors view CMS reimbursement and installed-base utilization as durable.
The article provides multiple concrete operating datapoints (revenue, system sales, installed base, procedure volume growth) and a specific policy catalyst (CMS proposed 2027 facility payment increase). However, it is a call transcript and the excerpt does not include full guidance or management’s detailed financial outlook.
Market effects
Reinforces investor narrative that focal therapy adoption is scaling via installed base and reimbursement tailwinds, potentially improving sentiment toward adjacent urology device/procedure platforms.
Highlights continued international commercialization (Europe, India, Latin America) and specific UK conversion and France HIFU coverage progress, which may support broader global adoption expectations.
CMS proposed Medicare facility payment increase is a US-specific policy lever that can influence global hospital investment decisions for Focal One.
Counterpoint
CMS figures are proposed, not final, and clinical expansion (BPH, endometriosis) depends on regulatory timing and trial outcomes that are not yet quantified here.
Key entities
- companyFocalTherics
Reports Q2 2026 HIFU revenue growth, Focal One system sales, installed base, procedure volume growth, and updates on FDA and CMS-related catalysts.
- regulatorFDA
Receives a 510(k) application submission for FocalConnect remote connectivity technology (submitted in July).
- regulatorCMS
Proposed an approximately 12% increase in HIFU facility payment for 2027 versus 2026, pending final rule.
- customerCleveland Clinic
Adds another Focal One placement in the quarter, described as the fourth in the US and sixth in their worldwide network.
